Floatz logo

Brexucabtagene Autoleucel

Relapsed/Refractory Waldenstrom Macroglobulinemia

Kite, A Gilead CompanyCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

59 Active assets in the Relapsed/Refractory Waldenstrom Macroglobulinemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BBB
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BBB
Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
PREDNISONE TABLETS
BeOne Medicines
Phase 2BBB
Inno-206
BeOne Medicines
Phase 2BBB

View all 50 →

Same molecule, other indications

Brexucabtagene Autoleucel is also rated in:

B-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
64 / 100
View asset →
mantle cell lymphomaDormant
B
Indicative ·
57 / 100
View asset →
hairy cell leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →